Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AK-105
/
Asahi Kasei
Welcome,
Profile
Billing
Logout
0 Diseases
0 Trials
0 Trials
10 News
||||||||||
penpulimab
(AK105) /
Akesobio, Sino Biopharm
[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
(On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1206;
P1/2, P1a/
Funding: Akeso Biopharma Inc. Clinical trial identification: NCT03352531; NCT04172506.
||||||||||
penpulimab
(AK105) /
Akesobio, Sino Biopharm
[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation antiprogrammed cell death1 (PD1) antibody, in upper gastrointestinal cancers
(On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_841;
P1/2, P1a/
Penpulimab in combination with anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, is being evaluated in phase III studies for 1L HCC (NCT04344158) and 2L Gastric/GEJ (NCT04385550). Akeso Biopharma Inc.
||||||||||
penpulimab
(AK105) /
Akesobio, Sino Biopharm
[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation antiprogrammed cell death1 (PD1) antibody, in upper gastrointestinal cancers
(On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_468;
P1/2, P1a/
Penpulimab in combination with anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, is being evaluated in phase III studies for 1L HCC (NCT04344158) and 2L Gastric/GEJ (NCT04385550). Akeso Biopharma Inc.